Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan
Links shared publicly online about this topic.
- 473total visits
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for NESINA® (alogliptin), combination therapy w
View full resource at medicalnewstoday.com
Tags: Diabetes, Type 2 Diabetes, Pharma
Most Recently Shared on February 28, 2011 at 5:05 pm By:
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide... http://mnt.to/3RGd
Also Shared By:
Furiex Pharmaceuticals / Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan
investor.furiex.com — “Furiex Pharmaceuticals / Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan” View full resource at investor.furiex.com
Most Recently Shared on February 28, 2011 at 5:58 pm By:
Symposier Endocrino Health Site
Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies for Type 2 Diabetes in Japan. http://bit.ly/fAoxP7
Advertisement
MNT Diabetes News
@mnt_diabetes
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide... http://mnt.to/3RGd
1 year ago...